We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Canada Offers Guidance on Developing Postmarket Benefit-Risk Assessment
Canada Offers Guidance on Developing Postmarket Benefit-Risk Assessment
Drugmakers providing postmarket benefit-risk assessments to Health Canada will soon need to follow rigid, standardized guidelines that provide both preapproval and postapproval data about a drug product’s efficacy.